Avrobio Inc (AVRO)
1.21
+0.02
(+2.11%)
USD |
NASDAQ |
Apr 26, 16:00
1.21
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 54.30M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 33.90% |
Valuation | |
PE Ratio | 4.481 |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 0.5731 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 98.90% |
Profile
Avrobio Inc is a clinical-stage gene therapy company. The company is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single-dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease. |
URL | https://www.avrobio.com |
Investor Relations URL | https://investors.avrobio.com/ |
HQ State/Province | Massachusetts |
Sector | |
Industry | |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Nov. 09, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Avrobio Inc is a clinical-stage gene therapy company. The company is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single-dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease. |
URL | https://www.avrobio.com |
Investor Relations URL | https://investors.avrobio.com/ |
HQ State/Province | Massachusetts |
Sector | |
Industry | |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Nov. 09, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |